Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Equivalents (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Cash & Equivalents for 11 consecutive years, with $125.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 41.14% to $125.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $125.1 million, a 41.14% decrease, with the full-year FY2025 number at $125.1 million, down 41.14% from a year prior.
  • Cash & Equivalents was $125.1 million for Q4 2025 at Cartesian Therapeutics, down from $143.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $219.2 million in Q3 2024 to a low of $76.9 million in Q4 2023.
  • A 5-year average of $128.8 million and a median of $119.9 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 176.44% in 2024, then tumbled 41.14% in 2025.
  • Cartesian Therapeutics' Cash & Equivalents stood at $114.1 million in 2021, then decreased by 6.68% to $106.4 million in 2022, then dropped by 27.74% to $76.9 million in 2023, then soared by 176.44% to $212.6 million in 2024, then plummeted by 41.14% to $125.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Cash & Equivalents are $125.1 million (Q4 2025), $143.4 million (Q3 2025), and $160.3 million (Q2 2025).